SINAPPS1 was a phase one study and it investigated the feasibility of delivering immunotherapy to patients with psychosis in a general hospital setting. The study was conducted from October 2015 to July 2017.

The SINAPP2 trial is a randomised, placebo-controlled clinical trial, investigating the efficacy and safety of immunotherapy as a treatment for symptoms of psychosis in patients with anti-neuronal membrane antibodies.

The PPiP1 study investigated prevalence of patients with anti-neuronal membrane antibodies included who were experiencing their first episode of psychosis in comparison with a group of healthy participants. The study was conducted from January 2013 – December 2014.